Invasive, deadly fungus affecting bats found in Rocky Mountain National Park
In a Thursday press release from the national park, tests done by the U.S. Geological Survey confirmed the fungus known as Pseudogymnoascus destructans, or Pd, has been detected in bats in the Holzwarth Historic Site on the west side of Rocky Mountain National Park.
According to the park, this is the first confirmed detection of the fungus in Grand County.
Pd is described as an invasive fungus that causes white-nose syndrome — a deadly and infectious disease that impacts bats.
'Any new detection of Pd is worrisome because bats are vital for healthy ecosystems. Rocky Mountain National Park is home to nine known species of bats, five of which have been found living in areas above 11,000 feet,' said Rocky Mountain National Park in a press release.
How much snow will fall in the high country this weekend?
While white-nose syndrome does not pose a risk to humans, people can spread the disease.
Following the detection, Rocky Mountain National Park has provided protection tips to visitors. The park asks people to report dead or injured bats to park personnel. The park also said people should never touch a bat, because they could carry other dangerous diseases aside from white-nose syndrome.
If you do visit a cave or bat habitat, Rocky Mountain National Park recommends you properly decontaminate gear and outerwear.
The national park said white-nose syndrome was first confirmed in 2022 in southeastern Colorado, it has also been confirmed in Larimer County.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
How much the COVID-19 pandemic aged our brains
NEW HAVEN, Conn. (WTNH) — In today's Health headlines, how much the COVID-19 pandemic aged our brains, the connection between sleep and alcohol consumption in young adults, and how high blood pressure impacts breastfeeding outcomes. Dr. F. Perry Wilson, associate professor at Yale School of Medicine, Yale Medicine physician, and author of 'How Medicine Works and When It Doesn't,' joined Good Morning Connecticut at 9 a.m. to discuss. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Business Wire
13 hours ago
- Business Wire
Delcath Systems to Host Second Quarter 2025 Earnings Call
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August 6, 2025, at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2025. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Participant Numbers: Toll Free: 1-877-407-3982 International: 1-201-493-6780 Webcast: A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website here. About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT ® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. In the United States, HEPZATO KIT is considered a combination drug and device product and is regulated and approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath's proprietary Hepatic Delivery System (HDS). The HDS is used to surgically isolate the liver while simultaneously filtrating hepatic venous blood during melphalan infusion and washout. The use of the HDS results in loco-regional delivery of a relatively high melphalan dose, which can potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduce systemic exposure. HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Please see the full Prescribing Information, including BOXED WARNING for the HEPZATO KIT. In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used in the conduct of percutaneous hepatic perfusion procedures at major medical centers to treat a wide range of cancers of the liver.
Business Wire
14 hours ago
- Business Wire
Spok Sets Date to Report Second Quarter 2025 Results
PLANO, Texas--(BUSINESS WIRE)--Spok Holdings, Inc. (NASDAQ: SPOK), a global leader in healthcare communications, today announced it will release its second quarter 2025 operating results on Wednesday, July 30, 2025, after the close of the U.S. financial markets. Management will host a conference call and webcast to discuss these financial results on Wednesday, July 30, 2025, at 5:00 p.m. ET. The presentation is open to all interested parties and may include forward-looking information. Conference Call Details To access the call, please dial in approximately ten minutes before the start of the call. For those unable to join the live call, an OnDemand version of the webcast will be available following the call under the URL link and on the investor relations website. About Spok Spok Holdings, Inc. (NASDAQ: SPOK), headquartered in Plano, Texas, is proud to be a global leader in healthcare communications. We deliver clinical information to care teams when and where it matters most to improve patient outcomes. Top hospitals rely on the Spok Care Connect® platform to enhance workflows for clinicians and support administrative compliance. Our customers send over 70 million messages each month through their Spok® solutions. Spok enables smarter, faster clinical communication. Spok is a trademark of Spok Holdings, Inc. Spok Care Connect and Spok Mobile are trademarks of Spok, Inc.
